Guardant Health stock declines amid broad market weakness
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 18 2024
0mins
Guardant Health Inc's stock fell by 5.04% as it crossed below its 5-day SMA, reflecting a challenging trading environment.
The decline in Guardant Health's stock price is primarily attributed to broad market weakness, with the Nasdaq-100 down 3.56% and the S&P 500 down 1.84%. This market trend has led to a sector rotation, impacting stocks like Guardant Health negatively despite any specific company news.
Investors are closely monitoring the overall market conditions, as the significant downturn in major indices suggests a cautious sentiment that could affect future trading in the healthcare sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GH
Wall Street analysts forecast GH stock price to fall
19 Analyst Rating
18 Buy
1 Hold
0 Sell
Strong Buy
Current: 125.610
Low
105.00
Averages
124.69
High
155.00
Current: 125.610
Low
105.00
Averages
124.69
High
155.00
About GH
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Grail: A Potential Sleeper Stock in Liquid Biopsies
- Massive Market Opportunity: With a market cap of approximately $2.6 billion, Grail focuses on early cancer detection through its Galleri test, which screens for over 50 cancer types, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, highlighting its significant potential in the projected $50 billion liquid biopsy market.
- Significant Clinical Results: At the 2026 American Society of Clinical Oncology Annual Meeting, Grail presented results from the NHS Galleri 2 and Pathfinder 2 trials, demonstrating that Galleri reduced stage IV diagnoses of 12 cancer types by over 20% and detected four times as many cancers when added to standard care, underscoring its effectiveness in early cancer detection.
- FDA Application Progress: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance, especially with the support of the Medicare Multi-Cancer Early Detection Screening Coverage Act.
- Investment Risks and Rewards: Despite reporting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, Grail's stock could skyrocket if it secures FDA approval and payer reimbursements, making it a focal point for patient investors.
See More
Grail's Multi-Cancer Early Detection Test Awaits FDA Approval
- Massive Market Potential: Grail's Galleri test screens for over 50 types of cancer, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, with the liquid biopsy market projected to reach $50 billion, highlighting significant commercial opportunities in early cancer detection.
- Positive Clinical Study Results: At the 2026 American Society of Clinical Oncology Annual Meeting, results from Galleri's NHS Galleri 2 and Pathfinder 2 trials showed over a 20% reduction in stage IV cancer diagnoses and a 16% increase in detection rates for stage I and II cancers, providing strong support for FDA approval.
- Optimistic FDA Approval Outlook: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance and sales growth.
- Investment Risks and Opportunities: Despite posting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, if Galleri secures FDA approval and payer reimbursements, its stock price could skyrocket, drawing increased investor attention.
See More
Latest Ratings and Outlook from Wall Street
- Qualcomm Investor Day: Qualcomm is set to host its highly anticipated Investor Day on June 24, discussing growth and diversification strategies in the rapidly evolving AI landscape; JPMorgan maintains a neutral rating but remains optimistic about future performance.
- Nvidia Buy Reiteration: Bank of America reiterates its buy rating on Nvidia after a meeting with management, highlighting the stock's strong performance across the board, particularly following the positive outlook shared during the GTC Taipei conference.
- Tesla Rating Upgrade: JPMorgan upgrades Tesla from underperform to neutral, citing its unique vertical integration across hardware and software products, which positions the company favorably for scaling in the industry.
- Disney Price Target Increase: Rosenblatt raises Disney's price target from $121 to $126, based on optimistic projections for its movie slate, particularly with the upcoming release of Toy Story 5, which is expected to drive earnings growth.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement
- Successful Financing: Q32 Bio announced a $55 million private placement, agreeing to issue 6.725 million shares at $8.00 each, with the financing expected to close on May 28, 2026, which will provide crucial funding for the company's ongoing research, particularly for its drug candidate Bempikibart targeting severe alopecia areata.
- Clinical Trial Progress: Bempikibart is currently undergoing a Phase 2a clinical trial, with topline data expected in mid-2026; early results indicate a 16% mean reduction in SALT scores at Week 24 for treated patients, demonstrating promising efficacy that could enhance the company's market performance.
- Positive Market Reaction: Following the financing announcement, Q32 Bio's stock surged over 85%, closing at $12.85, reflecting investor confidence in the company's growth potential and likely attracting further interest in its upcoming clinical developments.
- Significant Industry Impact: The successful financing and clinical trial outcomes will bolster Q32 Bio's competitiveness in the biotechnology sector, particularly in the alopecia treatment market, potentially generating new revenue streams and strengthening its market position.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
Grail: A Potential Sleeper Stock in Liquid Biopsies
- Massive Market Opportunity: With a market cap of approximately $2.6 billion, Grail focuses on early cancer detection through its Galleri test, which screens for over 50 cancer types, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, highlighting its significant potential in the projected $50 billion liquid biopsy market.
- Significant Clinical Results: At the 2026 American Society of Clinical Oncology Annual Meeting, Grail presented results from the NHS Galleri 2 and Pathfinder 2 trials, demonstrating that Galleri reduced stage IV diagnoses of 12 cancer types by over 20% and detected four times as many cancers when added to standard care, underscoring its effectiveness in early cancer detection.
- FDA Application Progress: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance, especially with the support of the Medicare Multi-Cancer Early Detection Screening Coverage Act.
- Investment Risks and Rewards: Despite reporting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, Grail's stock could skyrocket if it secures FDA approval and payer reimbursements, making it a focal point for patient investors.
See More
Grail's Multi-Cancer Early Detection Test Awaits FDA Approval
- Massive Market Potential: Grail's Galleri test screens for over 50 types of cancer, including ovarian, pancreatic, and liver/bile duct cancers that currently lack screening options, with the liquid biopsy market projected to reach $50 billion, highlighting significant commercial opportunities in early cancer detection.
- Positive Clinical Study Results: At the 2026 American Society of Clinical Oncology Annual Meeting, results from Galleri's NHS Galleri 2 and Pathfinder 2 trials showed over a 20% reduction in stage IV cancer diagnoses and a 16% increase in detection rates for stage I and II cancers, providing strong support for FDA approval.
- Optimistic FDA Approval Outlook: Grail submitted its application for full FDA approval of Galleri in January 2026, and if approved, insurers are likely to quickly begin reimbursing the test, further enhancing market acceptance and sales growth.
- Investment Risks and Opportunities: Despite posting a net loss of $93.2 million in Q1 2026 and facing competition from Exact Sciences and Guardant Health, if Galleri secures FDA approval and payer reimbursements, its stock price could skyrocket, drawing increased investor attention.
See More
Latest Ratings and Outlook from Wall Street
- Qualcomm Investor Day: Qualcomm is set to host its highly anticipated Investor Day on June 24, discussing growth and diversification strategies in the rapidly evolving AI landscape; JPMorgan maintains a neutral rating but remains optimistic about future performance.
- Nvidia Buy Reiteration: Bank of America reiterates its buy rating on Nvidia after a meeting with management, highlighting the stock's strong performance across the board, particularly following the positive outlook shared during the GTC Taipei conference.
- Tesla Rating Upgrade: JPMorgan upgrades Tesla from underperform to neutral, citing its unique vertical integration across hardware and software products, which positions the company favorably for scaling in the industry.
- Disney Price Target Increase: Rosenblatt raises Disney's price target from $121 to $126, based on optimistic projections for its movie slate, particularly with the upcoming release of Toy Story 5, which is expected to drive earnings growth.
See More
Latest Rating Changes on Wall Street
- TripAdvisor Upgrade: Wedbush upgraded TripAdvisor from neutral to outperform, citing the stock's undervaluation and expected governance transformation post-LTRIP merger, alongside activist involvement as catalysts for future growth.
- Knight-Swift Outlook: Susquehanna upgraded Knight-Swift from neutral to positive, highlighting strong earnings prospects in the trucking sector, although it noted that much of the good news is already priced in.
- Mobia Medical Coverage Initiation: Goldman Sachs initiated coverage on Mobia Medical with a buy rating and a $31 price target, indicating approximately 130% upside potential, reflecting the company's strong growth prospects in the medtech space.
- Intuit Downgrade: Goldman Sachs downgraded Intuit from neutral to sell, expressing concerns over heightened competition and noting a 46% year-to-date decline in stock price, which raises doubts about its future profitability.
See More
Q32 Bio Soars Over 85% on $55 Million Private Placement Announcement
- Successful Financing: Q32 Bio announced a $55 million private placement, agreeing to issue 6.725 million shares at $8.00 each, with the financing expected to close on May 28, 2026, which will provide crucial funding for the company's ongoing research, particularly for its drug candidate Bempikibart targeting severe alopecia areata.
- Clinical Trial Progress: Bempikibart is currently undergoing a Phase 2a clinical trial, with topline data expected in mid-2026; early results indicate a 16% mean reduction in SALT scores at Week 24 for treated patients, demonstrating promising efficacy that could enhance the company's market performance.
- Positive Market Reaction: Following the financing announcement, Q32 Bio's stock surged over 85%, closing at $12.85, reflecting investor confidence in the company's growth potential and likely attracting further interest in its upcoming clinical developments.
- Significant Industry Impact: The successful financing and clinical trial outcomes will bolster Q32 Bio's competitiveness in the biotechnology sector, particularly in the alopecia treatment market, potentially generating new revenue streams and strengthening its market position.
See More
Biotech Sector Regulatory Approvals and Collaborations
- Kidney Cancer Treatment Breakthrough: HUTCHMED and Innovent received NMPA approval in China for the ELUNATE-TYVYT combination therapy, supported by the FRUSICA-2 study showing a 63% reduction in disease progression or death risk, with a median progression-free survival of 22.2 months, significantly improving patient outcomes and enhancing market competitiveness.
- Antibiotic Market Expansion: Sunshine Biopharma received Canadian approval for its generic Amoxicillin, with shipments expected to begin in August 2026, aiming to increase access to high-quality antibiotics for treating common infections, which is anticipated to drive revenue growth for the company.
- Liquid Biopsy Technology Innovation: Guardant Health gained FDA approval for Guardant360 Liquid CDx, now the largest liquid biopsy panel with a genomic footprint 100 times broader than its predecessor, enhancing tumor profiling capabilities and expected to boost the company's market share in precision medicine.
- New Hypertension Drug Launch: AstraZeneca received FDA approval for BAXFENDY for hypertension patients, based on positive results from the BaxHTN Phase III trial, which is expected to strengthen the company's competitive position in the cardiovascular drug market and further expand its product line.
See More
